MENOPAUSE AND HORMONE REPLACEMENT THERAPY: BENEFITS AND RISKS

2025 NOVEMBER NEW RENAISSANCE INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE VOLUME 2 | ISSUE 11 310 MENOPAUSE AND HORMONE REPLACEMENT THERAPY: BENEFITS AND RISKS ¹Qaxxorova Zuhra ²Boyquvvatova Hulkar ³Allamurodova Zebiniso ¹'²'³ Clinical Coordinators of the Department of Obstetrics and Gynecology, DKTF No. 2, Samarkand State Medical University. https://doi.org/10.5281/zenodo.17692141 Introduction: Menopause represents a natural biological transition characterized by the permanent cessation of ovarian function, leading to significant changes in reproductive hormones, particularly estrogen and progesterone. These hormonal fluctuations contribute to a wide spectrum of clinical symptoms, including vasomotor instability, urogenital atrophy, mood disturbances, and long-term metabolic shifts affecting cardiovascular, skeletal, and cognitive health. Hormone Replacement Therapy (HRT) has emerged as the most effective therapeutic approach for managing moderate to severe menopausal symptoms; however, its use requires careful evaluation of individual risk factors, comorbidities, treatment duration, and formulation choice. The increasing prevalence of postmenopausal complications underscores the importance of understanding both the therapeutic potential and the safety concerns of HRT. Objective: To assess the clinical benefits and potential risks associated with Hormone Replacement Therapy in menopausal women and to evaluate its role in improving quality of life, symptom control, and long-term health outcomes. Materials and Methods: This thesis is based on a descriptive clinical review of contemporary literature, including randomized controlled trials, cohort studies, and guideline recommendations published over the past decade. Data were analyzed regarding symptom relief, bone density preservation, cardiovascular outcomes, thromboembolic risk, breast cancer incidence, and overall patient satisfaction. Inclusion criteria encompassed studies involving periand postmenopausal women receiving systemic or localized HRT. Exclusion criteria included studies not reporting clinical outcomes or lacking standardized therapeutic protocols. Results: Analysis revealed that HRT significantly reduces vasomotor symptoms by up to 75%, improves sleep, stabilizes mood, and enhances overall quality of life. Estrogen therapy demonstrated strong protective effects on bone mineral density, lowering the risk of osteoporotic fractures, particularly in early postmenopausal women. Local estrogen preparations provided marked improvement in urogenital atrophy and sexual dysfunction. However, systemic HRT was associated with an increased risk of venous thromboembolism and, in some formulations, a slightly elevated risk of breast cancer, particularly with prolonged combined estrogen-progestin therapy. Cardiovascular outcomes varied depending on patient age, initiation time, and underlying risk factors, with early initiation showing more favorable results compared to late initiation. 2025 NOVEMBER NEW RENAISSANCE INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE VOLUME 2 | ISSUE 11 311 Discussion: The findings highlight that HRT remains the most effective option for symptomatic menopause management, especially when initiated in women under 60 years of age or within 10 years of menopause onset. Benefits are most notable for vasomotor control, bone protection, and prevention of urogenital atrophy. Nevertheless, therapy must be individualized, balancing symptom severity with personal and familial risk factors, including cardiovascular history, thrombotic predisposition, and cancer susceptibility. Modern low-dose and transdermal formulations have shown improved safety profiles, reducing thrombotic risk while maintaining efficacy. Shared decision-making between clinicians and patients plays a crucial role in optimizing therapeutic outcomes and minimizing adverse effects. Conclusion: Hormone Replacement Therapy offers substantial clinical benefits for menopausal women, particularly in alleviating vasomotor symptoms, supporting bone health, and improving psychological and urogenital well-being. While certain risks such as thromboembolism and breast cancer require careful consideration, appropriate patient selection, individualized dosing, and ongoing clinical monitoring can significantly enhance treatment safety. HRT remains a valuable therapeutic tool when applied judiciously, with benefits outweighing risks in well-selected candidates, ultimately contributing to improved long-term health and quality of life during menopause. References 1. БЕЛКА, F. S. Р. С. Р. (2022). В ПАТОГЕНЕЗЕ СОСУДИСТЫХ ЗАБОЛЕВАНИЙ ОРГАНА ЗРЕНИЯ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. 2. Жалалова, Д. З., Кадирова, А. М., & Хамракулов, С. Б. (2021). Исходы герпетических кератоувеитов на фоне лечения препаратом «офтальмоферон» в зависимости от иммунного статуса пациентов. междисциплинарный подход по заболеваниям органов головы и шеи, 103. 3. ЖД, З., and А. БС. "РЕЗУЛЬТАТЫ ОЦЕНКИ УРОВНЯ ЭНДОТЕЛИНА-1 И ДДИМЕРОВ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ." SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES 3.3 (2024): 300-307. 4. Zhalalova, D. Z. OCT angiography in the assessment of retinal and choreoretinal microcirculation in patients with uncomplicated arterial hypertension International Ophthalmological Congress IOC Tashkent 2021. 5. Zhalalova, D. Z. Evaluation of markers of endothelial dysfunction in tear fluid in patients with arterial hypertension. Journal of Biomedicine in Amaliet. Tashkent-2022, Volume No., No. WITH. 6. Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210. 7. Jalalova, D., Axmedov, A., Kuryazov, A., & Shernazarov, F. (2022). Combined dental and eye pathology. Science and innovation, 1(8), 91-100. 2025 NOVEMBER NEW RENAISSANCE INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE VOLUME 2 | ISSUE 11 312 8. Zhalalova, D. Z. (2022). Pulatov US MICROCIRCULATORY DISORDERS IN THE VASCULAR SYSTEM OF THE BULBAR CONJUNCTIVA WITH INITIAL MANIFESTATIONS OF INSUFFICIENT BLOOD SUPPLY TO THE BRAIN. European journal of molecular medicine, 2(5). 9. Жалалова, Д. З. (2021). ОКТ-ангиография при оценке сосудистого русла сетчатки и хориоидеи. Биология ва тиббиет муаммолари, 6(130), 211-216. 10. Жалалова, Д. З. (2022). Классификационые критерии изменений сосудов сетчатки при артериальной гипертензии. In Международная научная конференция Университетская наука: взгляд в будущее (pp. 56-64). 11. Долиев, М. Н., Тулакова, Г. Э., Кадырова, А. М., Юсупов, З. А., & Жалалова, Д. З. (2016). Эффективность комбинированного лечения пациентов с центральной серозной хориоретинопатией. Вестник Башкирского государственного медицинского университета, (2), 64-66. 12. Жалалова, Д. З. Оценка маркеров эндотелиальной дисфункции в слезной жидкости у пациентов с артериальной гипертензиейЖурнал «Биомедицина ва амалиет». Тошкент-2022, Том №, №. С. 13. Жалалова, Д. З. (2021). ОКТ-ангиография в оценке ретинальной и хореоретинальной микроциркуляции у пациентов с неосложненой артериальной гипертензией/I Международный офтальмологческий конгресс IOC Uzbekistan, 2021 г. Ташкент, с, 96. 14. Shernazarov, F., Jalalova, D., Azimov, A., & CAUSES, S. A. (2022). SYMPTOMS, APPEARANCE, TREATMENT OF VARICOSE VEINS. 15. Жалалова, Д. З. (2021). Эндотелин-1 ва гомоцистеин даражасини артериал гипертензия фонида тур пардв узгаришларида эндотелиал дисфункциянинг маркерлари сифатида текшириш. Биомедицина ва амалиет журнали, 6(5), 203-210. 16. Shernazarov, F., Tohirova, J., & Jalalova, D. (2022). Types of hemorrhagic diseases, changes in newboens, their early diagnosis. Science and innovation, 1(D5), 16-22. 17. Zhalalova, D. Z. (2022). The content of endothelin and homocysteine in blood and lacrimal fluid in patients with hypertensive retinopathy Web of Scientist: International Scientific Research Journal. ISSUE, 2, 958-963. 18. Shernazarov, F., & Zuhridinovna, J. D. (2022). Microcirculation disorders in the vascular system of the bulbar conjunctiva in the initial manifestations of cerebral blood supply deficiency. Science and innovation, 1(Special Issue 2), 515-522. 19. Zhalalova, D. Z. (2022). Modern aspects of neuroprotektive treatment in hypertensive retinopathy Web of Scientist: International Scientific Research JournalVolume 3. ISSUE, 2, 949-952. 20. Жалалова, Д. З. (2009). Метод комбинированного лечения диабетической ретинопатии. Врач-аспирант, 37(10), 864-868. 21. Жалалова, Д. З. (2023). Результаты оценки эффективности комплексного лечения у пациентов с 3-4 стадиями гипертонической ангиоретинопатии. Miasto Przyszłości, 41, 33-36. 22. ЖД, З., & ИЖ, Ж. (2024). КЛАССИФИКАЦИЯ ГИПЕРТОНИЧЕСКОЙ РЕТИНОПАТИИ НА ОСНОВЕ ДАННЫХ ОПТИЧЕСКОЙ КОГЕРЕНТНОЙ 2025 NOVEMBER NEW RENAISSANCE INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE VOLUME 2 | ISSUE 11 313 ТОМОГРАФИИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 336-342. 23. ЗЖД, Ж. (2024). КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ПОКАЗАТЕЛИ ОРГАНА ЗРЕНИЯ У ПАЦИЕНТОВ С ИШЕМИЧЕКИМИ ИЗМЕНЕНИЯМИ СОСУДОВ СЕТЧАТКИ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 286-293. 24. ЖД, З. (2024). ОЦЕНКА КЛИНИЧЕСКИХ И ФУНКЦИОНАЛЬНЫХ ПОКАЗАТЕЛЕЙ ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ В СЛЕЗНОЙ ЖИДКОСТИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(3), 330-335. 25. Жалалова, Д. З. (2023). Актуальность проблемы изменений глазного дна при артериальной гипертензии. Miasto Przyszłości, 41, 37-40.